Print

Annual General Meeting of Active Biotech AB

2006-04-27

Board members Sven Andréasson, Mats Arnhög, Maria Borelius, Professor Klas Kärre, Peter Sjöstrand and Peter Ström were re-elected by the AGM. The AGM also decided to appoint Mats Arnhög as Chairman of the Board.
The AGM decided further that the Nomination Committee shall have the task of proposing a Chairman for the AGM, the Chairman of the Board and other Board members, Board remunerations and, when applicable, Auditors and remunerations for the Auditors. The Nomination Committee shall be composed of representatives for the three largest owners, as per December 31st, as well as the Chairman of the Board.
The AGM approved the Board's proposal for changes to the Articles of Association with the principal purpose to achieve compliance with the new Swedish Companies Act and the Board's proposal concerning a reduction of the share capital. Subsequent to the reduction, the company's share capital totals SEK 149,742,761 (or the higher amount that can be attributable to the conversion of outstanding convertibles).
The AGM approved the Board's proposal to authorize the Board to issue, on one or several occasions, with or without preferential rights, a maximum of 4,000,000 new shares and/or convertibles.
The AGM also approved the Board's proposal for adjustments to the 2003 employee stock options program, which permits an allocation of a maximum of 75,000 options per employee.
Lund, April 27, 2005
Active Biotech AB (Publ)
Sven Andréasson
President and CEO
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.

Active Biotech AB
Box 724, 220 07 Lund
Sweden
Tel +46 (0) 46-19 20 00
Fax +46 (0) 46-19 20 50
www.activebiotech.com

pdf



Back